Nothing Special   »   [go: up one dir, main page]

DOP2017000219A - Formulacion de combinacion de tesofensina y betabloqueante - Google Patents

Formulacion de combinacion de tesofensina y betabloqueante

Info

Publication number
DOP2017000219A
DOP2017000219A DO2017000219A DO2017000219A DOP2017000219A DO P2017000219 A DOP2017000219 A DO P2017000219A DO 2017000219 A DO2017000219 A DO 2017000219A DO 2017000219 A DO2017000219 A DO 2017000219A DO P2017000219 A DOP2017000219 A DO P2017000219A
Authority
DO
Dominican Republic
Prior art keywords
formulation
thessophensin
betablocking
combination
obesity
Prior art date
Application number
DO2017000219A
Other languages
English (en)
Inventor
G Nielsen Peter
S Thomsen Mikael
Højgaard Bent
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Publication of DOP2017000219A publication Critical patent/DOP2017000219A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una formulación de liberación controlada que comprende los compuestos activos tesofensina y un betabloqueante, tal como metoprolol o carvedilol, o una sal farmacéuticamente aceptable de los mismos. La invención también se refiere al uso de la formulación de liberación controlada en un método de tratamiento de diabetes, obesidad o un trastorno asociado a obesidad.
DO2017000219A 2015-03-03 2017-09-20 Formulacion de combinacion de tesofensina y betabloqueante DOP2017000219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201570117 2015-03-03
DKPA201570644 2015-10-09

Publications (1)

Publication Number Publication Date
DOP2017000219A true DOP2017000219A (es) 2018-02-15

Family

ID=55589632

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2017000219A DOP2017000219A (es) 2015-03-03 2017-09-20 Formulacion de combinacion de tesofensina y betabloqueante

Country Status (33)

Country Link
US (6) US9579288B2 (es)
EP (1) EP3265126B1 (es)
JP (1) JP6772430B2 (es)
KR (1) KR101999463B1 (es)
CN (1) CN107666913B (es)
AU (1) AU2016228002B2 (es)
CA (1) CA2977415A1 (es)
CL (1) CL2017002214A1 (es)
CO (1) CO2017009930A2 (es)
CR (1) CR20170447A (es)
DK (1) DK3265126T3 (es)
DO (1) DOP2017000219A (es)
EA (1) EA033298B1 (es)
EC (1) ECSP17059323A (es)
ES (1) ES2885437T3 (es)
GT (1) GT201700194A (es)
HK (1) HK1247127A1 (es)
HR (1) HRP20211361T1 (es)
HU (1) HUE055974T2 (es)
IL (1) IL254179B (es)
LT (1) LT3265126T (es)
MA (1) MA41634B1 (es)
MX (1) MX2017011257A (es)
PE (1) PE20180187A1 (es)
PH (1) PH12017501509B1 (es)
PL (1) PL3265126T3 (es)
PT (1) PT3265126T (es)
RS (1) RS62275B1 (es)
SA (1) SA517382209B1 (es)
SG (1) SG11201706899VA (es)
SI (1) SI3265126T1 (es)
UA (1) UA122224C2 (es)
WO (1) WO2016138908A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6203760B2 (ja) * 2012-02-16 2017-09-27 サニオナ・エー／エス 併用療法のための医薬組成物
PL3265126T3 (pl) 2015-03-03 2021-12-06 Saniona A/S Preparaty połączenia tesofensyny i metoprololu
WO2017121432A1 (en) 2016-01-15 2017-07-20 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
EP3426239A1 (en) * 2016-03-07 2019-01-16 Atrogi AB Compounds for the treatment of hyperglycaemia
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
MX2021008208A (es) * 2019-01-07 2021-11-17 Saniona As Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.
CA3176183A1 (en) 2020-04-22 2021-10-28 Jorgen Drejer Treatment of hypothalamic obesity
CN117045610B (zh) * 2023-08-24 2024-04-30 杭州沐源生物医药科技有限公司 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106494A1 (en) 1991-03-18 1992-09-19 James W. Young Composition and method containing optically pure (s) metoprolol
TR199801641T2 (xx) 1996-02-22 1998-11-23 Neurosearch A/S Tropan t�revleri bunlar�n haz�rlanmas� ve kullan�m�
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
WO2004069234A1 (en) 2003-02-05 2004-08-19 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
NZ547919A (en) 2004-01-22 2009-12-24 Neurosearch As Compounds for the sustained reduction of body weight
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
DE602006018529D1 (de) 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
PL1842534T3 (pl) * 2006-02-24 2012-05-31 Teva Pharma Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania
US20090068260A1 (en) * 2006-02-24 2009-03-12 Tomer Gold Beta-1-selective adrenoceptor blocking agent compositions and methods for their preparation
WO2007110753A2 (en) 2006-03-28 2007-10-04 Wockhardt Ltd Extended release dosage forms of metoprolol
DE102006020604A1 (de) 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
NZ574427A (en) 2006-07-28 2011-11-25 Zaklady Farmaceutyczne Polpharma S A Extended release pharmaceutical formulation of metoprolol and process for its preparation
US20110118304A1 (en) 2007-11-20 2011-05-19 Neurosearch A/S Method for treating over-eating disorders
CA2709861A1 (en) 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical compositions
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
CA2710665A1 (en) 2007-12-27 2009-07-09 Bayer Animal Health Gmbh Treatment of heart disease using .beta.-blockers
EP2406253B1 (en) 2009-03-11 2013-07-03 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
WO2011078993A1 (en) 2009-12-21 2011-06-30 Aptapharma, Inc. Functionally-coated multilayer tablets
CN102145000A (zh) * 2010-02-06 2011-08-10 赤峰维康生化制药有限公司 一种坎地沙坦酯和美托洛尔复方制剂
WO2011100659A2 (en) 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
CN102198112A (zh) * 2010-03-26 2011-09-28 北京天衡药物研究院 一种渗透泵型控释片及其制备方法
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
CN102762198A (zh) * 2010-05-15 2012-10-31 欢腾生命科学有限公司 多单元组合物
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
CN102085195A (zh) * 2011-01-10 2011-06-08 中国药科大学 琥珀酸美托洛尔缓释片及其制备方法
EA201391643A1 (ru) 2011-05-06 2014-07-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Составы с замедленным высвобождением парацетамола
CA2840765A1 (en) 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Multilayered dosage form
CN103906508A (zh) 2011-08-26 2014-07-02 沃克哈特有限公司 治疗心血管疾病的方法
US20140329781A1 (en) 2011-12-09 2014-11-06 Wockhardt Limited Methods for treating cardiovascular disorder
JP6203760B2 (ja) 2012-02-16 2017-09-27 サニオナ・エー／エス 併用療法のための医薬組成物
IN2012DE00826A (es) 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102626396B (zh) * 2012-04-28 2014-05-07 海南华益泰康药业有限公司 一种美托洛尔缓释片剂及其制备方法
EP3019160A1 (en) 2013-07-09 2016-05-18 Sun Pharmaceutical Industries Ltd Extended-release pharmaceutical compositions of metoprolol
PL3265126T3 (pl) 2015-03-03 2021-12-06 Saniona A/S Preparaty połączenia tesofensyny i metoprololu

Also Published As

Publication number Publication date
EA201791875A1 (ru) 2017-12-29
ECSP17059323A (es) 2018-06-30
HK1247127A1 (zh) 2018-09-21
MA41634B1 (fr) 2021-09-30
GT201700194A (es) 2019-06-12
DK3265126T3 (da) 2021-09-13
JP6772430B2 (ja) 2020-10-21
IL254179A0 (en) 2017-10-31
IL254179B (en) 2020-11-30
US9579288B2 (en) 2017-02-28
HRP20211361T1 (hr) 2021-11-26
AU2016228002A1 (en) 2017-09-14
EP3265126A1 (en) 2018-01-10
CL2017002214A1 (es) 2018-04-13
SA517382209B1 (ar) 2021-04-19
EP3265126B1 (en) 2021-06-02
US20200129478A1 (en) 2020-04-30
CN107666913B (zh) 2021-11-26
US20180071250A1 (en) 2018-03-15
KR101999463B1 (ko) 2019-10-01
US10231951B2 (en) 2019-03-19
SG11201706899VA (en) 2017-09-28
AU2016228002B2 (en) 2020-10-01
LT3265126T (lt) 2021-09-10
SI3265126T1 (sl) 2021-11-30
PE20180187A1 (es) 2018-01-23
CN107666913A (zh) 2018-02-06
BR112017018871A2 (pt) 2018-04-17
US20160279067A1 (en) 2016-09-29
US12016840B2 (en) 2024-06-25
UA122224C2 (uk) 2020-10-12
PH12017501509A1 (en) 2018-02-05
PT3265126T (pt) 2021-08-30
CO2017009930A2 (es) 2018-01-05
ES2885437T3 (es) 2021-12-13
CR20170447A (es) 2018-03-13
US20210023050A1 (en) 2021-01-28
MA41634A (fr) 2018-01-09
HUE055974T2 (hu) 2022-01-28
US20230092397A1 (en) 2023-03-23
CA2977415A1 (en) 2016-09-09
US20180360804A1 (en) 2018-12-20
JP2018507875A (ja) 2018-03-22
US11426383B2 (en) 2022-08-30
PH12017501509B1 (en) 2018-02-05
RS62275B1 (sr) 2021-09-30
MX2017011257A (es) 2018-04-10
EA033298B1 (ru) 2019-09-30
PL3265126T3 (pl) 2021-12-06
KR20170134393A (ko) 2017-12-06
WO2016138908A1 (en) 2016-09-09
US10828278B2 (en) 2020-11-10
US10537551B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
DOP2017000219A (es) Formulacion de combinacion de tesofensina y betabloqueante
CL2017003404A1 (es) Compuestos antibacterianos
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
ECSP19021223A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
AR102712A1 (es) Agonistas parciales del receptor de insulina
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CR20170129A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
DK3492455T3 (da) 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer
CL2016000313A1 (es) Compuestos de benzoxaborol tricíclicos y usos de los mismos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
NI201800071A (es) Compuestos de isoindol
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer